16 results about "Hemofiltration" patented technology

The invention discloses a kidney organoid culture and multifunctional detection integrated micro-fluidic chip, which is characterized in that a first chip (top layer) is provided with six independent cell culture chambers, the bottom is provided with a porous membrane, glomerular cells differentiated by human induced pluripotent stem cells are inoculated, and a blood filtration function is simulated; the second chip (middle layer) is provided with a raw urine-like collecting chamber, and a porous membrane is used for receiving the filtrate and detecting final urine-like components; and the third chip (bottom layer) is inoculated with vascular endothelial cells to simulate renal tubule reabsorption and blood purification processes. According to the invention, glomerular filtration and renal tubule reabsorption full-function chains are coupled, and the limitation of single function simulation is broken through; the parallel culture room supports synchronous drug toxicity testing or disease modeling; a multi-valve dynamic control system can accurately simulate pathological microenvironments such as high glucose and renal toxicity; and in-situ multi-parameter real-time analysis is realized through three paths of detection outlets. The chip provides a highly bionic in-vitro platform for drug screening, diabetic nephropathy mechanism research and kidney injury model construction.

An artificial kidney configured to automatically or semi-automatically perform priming, procedure running, purging, flushing, and procedure ending. The artificial kidney is wearable and can be used while ambulating, sitting, and lying down. The artificial kidney can be used at home as a supplement to standard intermittent hemodialysis therapy in the clinic. In an example, the artificial kidney can be configured to perform alert event detection, start a timer, and take steps to resolving the alert event. The steps can include automated steps and can include instructions to be manually performed by the user (or the patient). If the alert event is resolved within a set time, the artificial kidney can continue to perform procedure running. If the alert event is not resolved within the set time, the artificial kidney performs the procedure ending.

A renal replacement apparatus (100), having a hemofilter (108); an extracorporeal blood circuit (102) configured to communicate blood from a patient (104), through the hemofilter, and back to the patient; and a flow measuring device (150) configured to measure at least one blood flow property as the blood is leaving the hemofilter and before the blood returns to the patient at a flow measuring device location (152), wherein the flow measuring device comprises at least one of a viscometer and a rheometer. Alternately, or in addition, the renal replacement apparatus may include thermomodulator system (222) including at least one thermomodulator configured to selectively heat and cool the blood in the extracorporeal blood circuit. The renal replacement apparatus (100) may have a controller (160). The controller may use artificial intelligence. Other embodiments are described herein.

An artificial kidney configured to automatically or semi-automatically perform priming, procedure running, purging, flushing, and procedure ending. The artificial kidney is wearable and can be used while ambulating, sitting, and lying down. The artificial kidney can be used at home as a supplement to standard intermittent hemodialysis therapy in the clinic. In an example, the artificial kidney can be configured to perform alert event detection, start a timer, and take steps to resolving the alert event. The steps can include automated steps and can include instructions to be manually performed by the user (or the patient). If the alert event is resolved within a set time, the artificial kidney can continue to perform procedure running. If the alert event is not resolved within the set time, the artificial kidney performs the procedure ending.

This invention provides a bedside hemofiltration method and system for elderly critically ill patients, comprising: analyzing the correlation between transmembrane pressure changes and venous pressure fluctuations under the control of vascular access type and puncture angle, based on a dynamic trend description, and simultaneously evaluating the corrective effect of signal compensation mechanisms on data accuracy to obtain a set of parameter correlation strengths; if some values ​​in the parameter correlation strength set exceed a preset threshold, then combining monitoring data on access infection risk and fluctuations in signal transmission distance, determining whether there is a chain reaction caused by access abnormality, and obtaining an abnormal chain reaction identifier; for the abnormal chain reaction identifier, determining the degree of danger of the abnormality to the overall system by analyzing the matching degree between access establishment time and attenuation frequency range, and obtaining a danger level classification result.

The invention provides a sterilization process of a glucose-containing double-chamber bag blood filtration replacement liquid, a to-be-sterilized product is a filled and sealed blood filtration replacement liquid, the sterilization adopts a moist heat sterilization process, the sterilization temperature is 121 DEG C, the heating time is 1500-3800 s, the sterilization time is 25-30 min, and the cooling time is greater than or equal to 2000 s. The sterilization process is simple and easy to operate, the method is stable, and it is ensured that the content of 5-hydroxymethylfurfural in a blood filtration replacement liquid A chamber is at a low level after sterilization; b, a chamber sterilization exposure stage: 121 DEG C is greater than 12min; the sterile standard level of the obtained glucose-containing double-chamber bag blood filtration replacement liquid reaches the standard within 18 months, the validity period reaches 18 months, and the glucose-containing double-chamber bag blood filtration replacement liquid has very good market circulation and clinical use values.

The utility model relates to a blood filtration pipeline fixing device, which belongs to the technical field of blood filtration application, and comprises a bandage, a fixing strip and a plurality of fixing blocks, the fixing blocks are fixedly arranged on the bandage, the top of each fixing block is provided with a first groove and a second groove, the first groove and the second groove are distributed in a crossed manner, the fixing blocks are provided with fixing grooves, and the fixing grooves are communicated with the first groove and the second groove. The fixing groove penetrates through the first groove, the fixing strip penetrates through the fixing groove, and one section of the fixing strip is arranged between the fixing block and the bandage. The fixing device can fix pipelines in two directions, and can adapt to pipelines of different sizes for wire arrangement.

Traditional hemofiltration devices can include a linear blood channel, a linear dialysate channel, or both. Additionally, the blood channel or dialysate channel can be modified so that one region has a recess in a channel wall and a filtration membrane can be positioned along the edge of the recess. However, due to fluid dynamics, some blood or dialysate could linger within the recess by moving slowly. Therefore, other fractions of the blood or dialysate would simply bypass the recess and filtration membrane by flowing through the center of the channel. This flow pattern would reduce filtration efficiency since some blood or dialysate remains far from the filtration membrane. However, positioning a flow diverter adjacent to the recess could force most or all of the blood or dialysate into the recess, thereby increasing filtration efficiency. In other words, the flow diverter would modify the fluid dynamics in a manner that would reduce the dead space in the blood channel or dialysate channel and increase filtration efficiency.

The invention relates to a medical device (1), preferably a dialysis apparatus for performing hemodialysis and / or hemofiltration and / or hemodiafiltration, comprising a first functional module (CPU1) and a second functional module (CPU2), wherein a chronograph (2) for counting an operating time is provided in the first functional module (CPU1) and the first functional module (CPU1) is configured to store an operating time value determined by the chronograph (2) in a first memory (M1) of the first functional module (CPU1), wherein a second memory (M2) is provided in the second functional module (CPU2), wherein the second functional module (CPU2) is configured to store the operating time value determined by the chronograph (2) of the first functional module (CPU1) in the second memory (M2).

The present application relates to a kind of high-pressure discharge leak detection methods of double-chamber bag packaging system, belong to the technical field of drug detection.The method includes the following steps: preparation contains 3~10 μm pore size double-chamber positive sample and negative sample, carry out high-pressure discharge detection under (7~8) ±0.1KV output voltage, 250~300Hz frequency, respectively record minimum positive detection value M min And maximum negative detection value M max , according to formula (M min +m max ) / 2 Calculate leakage threshold (and 1.5m max ≤M min ).The present application breaks through the limitation of traditional step-by-step detection, realizes double-chamber synchronous leak detection, avoids the parameter switching and electrode error caused by chamber detection, is suitable for different pH complex preparation (such as sodium bicarbonate hemofiltration replacement fluid etc.), can detect ≥3 μm micro leakage, detection efficiency is doubled, result is accurate and reliable, and cost is significantly reduced, effectively guarantees the quality of product and clinical drug safety.

A modified hemofiltration method for clearing peripheral α-synuclein aggregates in patients with neurodegenerative diseases is provided, which falls into the field of medicine. Specifically, a ratio S of synuclein dimers in blood is obtained; a blood flow velocity and an exchange membrane area for hemofiltration are determined through clinical trial data or historical literature data; hemofiltration is performed by the determined blood flow velocity and exchange membrane area, a calculation model of the ratio S of different synuclein dimers and an exchange membrane aperture D required for hemofiltration is constructed by linear regression; a clearance rate of synuclein dimers can be estimated by setting hemofiltration parameters with the calculation model. It is found that hemofiltration is beneficial to reducing the level of peripheral α-synuclein aggregates in patients with neurodegenerative diseases. Therefore, the calculation model is constructed, which provides scientific data and a new solution for clinically relieving α-synuclein-related toxicity symptoms.

The utility model discloses a blood filter blocking conversion device which comprises a pipe body and a plurality of film terminals, the upper end and the lower end of the pipe body are communicated, a puncture device is arranged on the upper portion of the pipe body, a blood return device is installed on the lower portion of the pipe body, a first connecting pipe connected with a blood filter is arranged on the side face of the pipe body, and the film terminals are connected with the first connecting pipe. The thin film terminals are installed at the pipe opening of the first connecting pipe, the thin film terminals are also installed at the upper end of the puncture device, and the blood return device is matched with the two thin film terminals; when the device is used and the blood filter needs to be replaced, only the puncture device needs to be driven to slide down, so that the puncture device is communicated with the blood return device, arterial blood does not pass through the blood filter but directly flows back through the blood return device, the blood filter can be directly replaced, and the problem of blood leakage does not need to be worried about.

A system and method for preparing a cancer vaccine (and optionally purifying blood) comprises a hemofiltration system controlled by a control unit for filtering exogenous plasma to isolate tumor cells, tumor stem cells, and tumor degradation products. The hemofiltration system filter may include multiple layers with openings of different sizes to hold substances of different sizes (from among tumor cells, tumor stem cells, and tumor degradation products of different sizes). The apparatus directs electromagnetic radiation to the isolated tumor cells, tumor stem cells, and / or tumor degradation products, which can cause a coagulated outer layer by degrading the outer surface of the isolated tumor cells, isolated tumor stem cells, and / or isolated tumor degradation products (e.g., tumor proteins such as DNA and / or tumor exosomes). The electromagnetic radiation may have a UV wavelength. A conical coil improves flow uniformity. Tumor exosomes can be centrifuged.

This invention relates to the field of biomedical polymer materials technology, specifically to a polyethersulfone-based material with blood purification and anticoagulation functions, its preparation method, and its applications. The polyethersulfone-based material uses polyethersulfone as the main component, and a stable multi-coordination network structure is constructed by introducing terpyridine ligands and multivalent metal ions at the molecular level. Furthermore, the anticoagulant active molecules argatroban or heparin are immobilized on its surface, achieving selective adsorption of blood toxins and synergistic regulation of the anticoagulation reaction. The material is prepared using a process combining phase inversion membrane formation technology and surface coordination modification, resulting in a composite interface on the membrane surface rich in hydrophilic groups and a stable anticoagulant layer, significantly improving blood compatibility and membrane flux stability. This composite membrane can simultaneously perform purification and anticoagulation functions in hemodialysis, hemofiltration, and extracorporeal circulation systems, exhibiting good mechanical strength, chemical stability, and biosafety. The preparation route of this invention is simple, the parameters are controllable, and it is suitable for large-scale production.

The present invention relates to a continuous process for the preparation of selectively permeable hollow fiber membranes suitable for use in hemodialysis, hemodiafiltration and hemofiltration of, for example, blood, which comprises a two-stage drying and tempering treatment of the hollow fiber membranes. According to a further aspect, the present invention relates to a continuous process for the in-line drying of selectively permeable hollow fiber membranes. The present invention also relates to an apparatus for the in-line drying of selectively permeable hollow fiber membranes.

This invention relates to a hemodialysis membrane with an in-situ anticoagulant protective layer constructed using interfacial polymerization, its preparation method, and its applications, belonging to the field of medical membrane materials technology. The method involves a wet spinning process, in which a grafting agent is added to the spinning solution, and an anticoagulant is added to the core solution and coagulation bath. An interfacial polymerization reaction is then used to simultaneously form an anticoagulant protective layer on both the inner and outer surfaces of the membrane in situ. The hemodialysis membrane prepared by this invention exhibits excellent anticoagulant properties and biocompatibility, making it suitable for medical applications such as hemodialysis and hemofiltration. The process is simple, controllable, and easily scalable.